Formation Bio vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-Native Drug Development & Clinical Asset Acceleration
Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drug assets and accelerates their development to market using proprietary AI and operational technology; raised $372M in a 2024 Series D;
About
Formation Bio (formerly TrialSpark) is a New York-based AI-native pharmaceutical company founded in 2016 by Nicky Popp and Benjamine Liu. The company operates at the intersection of artificial intelligence and drug development, acquiring clinical-stage pharmaceutical assets — compounds that have demonstrated early safety and efficacy in human trials — and applying proprietary AI and operational technology to accelerate their development timelines and reduce costs. Rather than discovering new drug targets from scratch, Formation Bio's model focuses on execution excellence: identifying undervalued clinical assets and getting them to patients faster and more cheaply than traditional pharma development organizations can.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.